IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0248238.html
   My bibliography  Save this article

A comparison of educational events for physicians and nurses in Australia sponsored by opioid manufacturers

Author

Listed:
  • Quinn Grundy
  • Sasha Mazzarello
  • Sarah Brennenstuhl
  • Emily A Karanges

Abstract

Background: Educational activities for physicians sponsored by opioid manufacturers are implicated in the over- and mis-prescribing of opioids. However, the implications of promotion to nurses are poorly understood. Nurses play a key role in assessing pain, addressing the determinants of pain, and administering opioid medications. We sought to understand the nature and content of pain-related educational events sponsored by opioid manufacturers and to compare events targeting physicians and nurses. Methods: We conducted a cross sectional, descriptive analysis of pharmaceutical company reports detailing 116,845 sponsored educational events attended by health professionals from 2011 to 2015 in Australia. We included events that were sponsored by manufacturers of prescription opioid analgesics and were pain related. We compared event characteristics across three attendee groups: (a) physicians only; (b) at least one nurse in attendance; and (c) nurses only. We coded the unstructured data using iteratively generated keywords for variables related to location, format, and content focus. Results: We identified 3,411 pain-related events sponsored by 3 companies: bioCSL/CSL (n = 15), Janssen (n = 134); and Mundipharma (n = 3,262). Pain-related events were most often multidisciplinary, including at least one nurse (1,964/3,411; 58%); 38% (1,281/3,411) included physicians only, and 5% (166/3,411) nurses only. The majority of events were held in clinical settings (61%) and 43% took the form of a journal club. Chronic pain was the most common event topic (26%) followed by cancer pain and palliative care (18%), and then generic or unspecified references to pain (15%); nearly a third (32%) of event descriptions contained insufficient information to determine the content focus. Nurse-only events were less frequently held in clinical settings (32%; p

Suggested Citation

  • Quinn Grundy & Sasha Mazzarello & Sarah Brennenstuhl & Emily A Karanges, 2021. "A comparison of educational events for physicians and nurses in Australia sponsored by opioid manufacturers," PLOS ONE, Public Library of Science, vol. 16(3), pages 1-18, March.
    • Handle: RePEc:plo:pone00:0248238
    DOI: 10.1371/journal.pone.0248238
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0248238
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0248238&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0248238?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Van Zee, A., 2009. "The promotion and marketing of oxycontin: Commercial triumph, public health tragedy," American Journal of Public Health, American Public Health Association, vol. 99(2), pages 221-227.
    2. Jane Robertson & Ray Moynihan & Emily Walkom & Lisa Bero & David Henry, 2009. "Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals," PLOS Medicine, Public Library of Science, vol. 6(11), pages 1-5, November.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Louis‐Philippe Beland & Jason Huh & Dongwoo Kim, 2024. "The effect of opioid use on traffic fatalities," Health Economics, John Wiley & Sons, Ltd., vol. 33(6), pages 1123-1132, June.
    2. William Encinosa & Didem Bernard & Thomas M. Selden, 2022. "Opioid and non-opioid analgesic prescribing before and after the CDC’s 2016 opioid guideline," International Journal of Health Economics and Management, Springer, vol. 22(1), pages 1-52, March.
    3. Abhimanyu Sud & Darren K. Cheng & Rahim Moineddin & Erin Zlahtic & Ross Upshur, 2021. "Time series-based bibliometric analysis of a systematic review of multidisciplinary care for opioid dose reduction: exploring the origins of the North American opioid crisis," Scientometrics, Springer;Akadémiai Kiadó, vol. 126(11), pages 8935-8955, November.
    4. Ravi Katari, Dean Baker, 2015. "Patent Monopolies and the Costs of Mismarketing Drugs," CEPR Reports and Issue Briefs 2015-11, Center for Economic and Policy Research (CEPR).
    5. Johanna Catherine Maclean & Justine Mallatt & Christopher J. Ruhm & Kosali Simon, 2022. "The Opioid Crisis, Health, Healthcare, and Crime: A Review of Quasi-Experimental Economic Studies," The ANNALS of the American Academy of Political and Social Science, , vol. 703(1), pages 15-49, September.
    6. McGranahan, David A. & Parker, Timothy S., 2021. "The Opioid Epidemic: A Geography in Two Phases," USDA Miscellaneous 310390, United States Department of Agriculture.
    7. Deiana, Claudio & Giua, Ludovica & Nistico, Roberto, 2019. "The Economics behind the Epidemic: Afghan Opium Price and Prescription Opioids in the US," IZA Discussion Papers 12872, Institute of Labor Economics (IZA).
    8. Joel Piqué-Buisan & Josep-E Baños & Irene Cambra-Badii, 2024. "Telling the story of the opioid crisis: A narrative analysis of the TV series Dopesick," PLOS ONE, Public Library of Science, vol. 19(4), pages 1-20, April.
    9. Anne Case & Angus Deaton, 2017. "Mortality and Morbidity in the 21st Century," Brookings Papers on Economic Activity, Economic Studies Program, The Brookings Institution, vol. 48(1 (Spring), pages 397-476.
    10. James F. Anderson & Kelley Reinsmith-Jones & Willie M. Brooks, Jr. & Adam H. Langsam, 2017. "Paradigm Shift in Responding to Drug Users and Addicts: From a Criminal Justice to a Public Health Approach," International Journal of Social Science Studies, Redfame publishing, vol. 5(5), pages 1-15, May.
    11. Shannon M. Monnat, 2022. "Demographic and Geographic Variation in Fatal Drug Overdoses in the United States, 1999–2020," The ANNALS of the American Academy of Political and Social Science, , vol. 703(1), pages 50-78, September.
    12. Boslett, Andrew & Hill, Elaine, 2022. "Mortality during resource booms and busts," Journal of Environmental Economics and Management, Elsevier, vol. 115(C).
    13. McGranahan, David & Parker, Timothy, 2021. "The Opioid Epidemic: A Geography in Two Phases," Economic Research Report 327197, United States Department of Agriculture, Economic Research Service.
    14. Jessica Y. Ho, 2019. "The Contemporary American Drug Overdose Epidemic in International Perspective," Population and Development Review, The Population Council, Inc., vol. 45(1), pages 7-40, March.
    15. Francisco A. Montiel Ishino & Tamika Gilreath & Faustine Williams, 2020. "Finding the Hidden Risk Profiles of the United States Opioid Epidemic: Using a Person-Centered Approach on a National Dataset of Noninstitutionalized Adults Reporting Opioid Misuse," IJERPH, MDPI, vol. 17(12), pages 1-14, June.
    16. Shiyu Zhang & Daniel Guth, 2021. "The OxyContin Reformulation Revisited: New Evidence From Improved Definitions of Markets and Substitutes," Papers 2101.01128, arXiv.org, revised Jan 2021.
    17. Yang, Tse-Chuan & Shoff, Carla & Kim, Seulki, 2022. "Social isolation, residential stability, and opioid use disorder among older Medicare beneficiaries: Metropolitan and non-metropolitan county comparison," Social Science & Medicine, Elsevier, vol. 292(C).
    18. David M. Cutler & Edward L. Glaeser, 2021. "When Innovation Goes Wrong: Technological Regress and the Opioid Epidemic," NBER Working Papers 28873, National Bureau of Economic Research, Inc.
    19. Francis W. Graham & Sonja de New & Suzanne Nielsen & Dennis Petrie, 2023. "Revisiting the OxyContin reformulation: The role of licit substitutes," Papers 2023-09, Centre for Health Economics, Monash University.
    20. van Amsterdam, Jan & Phillips, Lawrence D. & Henderson, Graeme & Bell, James & Bowden-Jones, Owen & Hammersley, Richard & Ramsey, John & Taylor, Polly & Dale-Perera, Annette & Melichar, Jan & van den , 2015. "Ranking the harm of non-medically used prescription opioids in the UK," LSE Research Online Documents on Economics 64653, London School of Economics and Political Science, LSE Library.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0248238. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.